MoonLake Immunotherapeutics (MLTX) stock is higher by 416.01% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary ranking system, gives MLTX stock a score of 80 out of a possible 100.
That rank is primarily influenced by a long-term technical score of 82. MLTX's rank also includes a short-term technical score of 72.
MLTX has an Overall Score of 80. Find out what this means to you and get the rest of the rankings on MLTX!
MoonLake Immunotherapeutics (MLTX) stock has risen 10.87% while the S&P 500 is higher by 0.21% as of 12:08 PM on Tuesday, Nov 7. MLTX is higher by $3.95 from the previous closing price of $36.35 on volume of 759,739 shares. Over the past year the S&P 500 is higher by 14.93% while MLTX is higher by 416.01%. MLTX lost -$0.91 per share in the over the last 12 months.
Click Here to get the full Stock Report for MoonLake Immunotherapeutics stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
